NRx Pharmaceuticals (NASDAQ:NRXP) Given Buy Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report released on Friday morning,Benzinga reports. They currently have a $31.00 price objective on the stock.

A number of other research firms have also weighed in on NRXP. BTIG Research began coverage on NRx Pharmaceuticals in a research note on Wednesday, April 2nd. They issued a “buy” rating and a $18.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $19.00 price target on shares of NRx Pharmaceuticals in a report on Thursday, March 20th. Ascendiant Capital Markets lifted their price objective on shares of NRx Pharmaceuticals from $45.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, April 29th. Finally, Wall Street Zen raised shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $28.50.

NRx Pharmaceuticals Trading Up 0.9%

NRx Pharmaceuticals stock opened at $3.26 on Friday. NRx Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $6.01. The firm has a 50-day moving average price of $2.53 and a 200-day moving average price of $2.46. The firm has a market capitalization of $56.37 million, a PE ratio of -1.62 and a beta of 1.54.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. The firm had revenue of $1.14 million during the quarter, compared to analysts’ expectations of $1.14 million. As a group, sell-side analysts predict that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in NRXP. Anson Funds Management LP increased its position in NRx Pharmaceuticals by 535.1% during the 1st quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock valued at $2,417,000 after purchasing an additional 993,401 shares during the period. AdvisorShares Investments LLC boosted its stake in shares of NRx Pharmaceuticals by 138.5% during the fourth quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock valued at $683,000 after purchasing an additional 180,229 shares in the last quarter. Millennium Management LLC bought a new position in shares of NRx Pharmaceuticals during the fourth quarter valued at approximately $61,000. Squarepoint Ops LLC purchased a new position in NRx Pharmaceuticals during the fourth quarter valued at approximately $56,000. Finally, Sassicaia Capital Advisers LLC bought a new position in NRx Pharmaceuticals in the fourth quarter worth approximately $33,000. 4.27% of the stock is owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.